Tadalafil Tablet, Film Coated
Product Images NDC 71205-269

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71205-269). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tadalafil Figure1)

A set of four line graphs showing the difference in blood pressure (mmHg) between Tadalafil and placebo over time (hours). The graphs depict standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure changes, with time on the x-axis and blood pressure difference on the y-axis, including error bars for variability.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs showing changes in standing and supine systolic blood pressure (BP) over 24 hours post-dose. The top graph depicts standing systolic BP with two lines representing Tadalafil 20 mg & doxazosin 8 mg versus placebo & doxazosin 8 mg. The bottom graph shows supine systolic BP over the same timeframe with the same comparison.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph displaying the effect on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. The graph shows four groups: 20 mg tadalafil at 8:00 with 8 mg doxazosin, placebo at 8:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin, illustrating fluctuations in blood pressure measurements over time.*

FDA Label Image

Figure (Tadalafil Figure4)

A pharmacokinetic line graph depicting plasma tadalafil concentration (µg/L) over time (hours) following different dosing regimens. The graph includes curves for a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing after 5 consecutive days, with error bars showing variability at each time point.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS Total Score over 12 weeks of treatment. It compares tadalafil 5 mg (solid line with circles) with placebo (dashed line with triangles), with tadalafil demonstrating a greater decrease in scores over time. The x-axis represents treatment duration in weeks, and the y-axis represents change in IPSS Total Score.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between tadalafil 5 mg and placebo. The x-axis shows duration of treatment in weeks (0, 1, 4, 8, 12) and the y-axis shows change in IPSS total score. Tadalafil shows a greater reduction in score compared to placebo, with statistical significance indicated (p<0.01).*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line chart depicting Least Squares Mean Change from Baseline over 26 weeks of therapy comparing Tadalafil/Finasteride versus Placebo/Finasteride. The x-axis shows weeks of therapy (0, 4, 12, 26), and the y-axis shows change from baseline ranging from 0 to -7. Tadalafil/Finasteride shows a greater decline with marked statistical significance at weeks 4 and 12 and less at week 26 compared to placebo.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph comparing the change from baseline in IPSS (International Prostate Symptom Score) total score over a 12-week duration of treatment. The graph shows two lines representing tadalafil 5 mg and placebo, with tadalafil demonstrating a greater decrease in IPSS score over time. The x-axis indicates treatment duration in weeks, and the y-axis shows the change from baseline in IPSS total score. A statistical significance marker (* p<0.01) is included.*

FDA Label Image

71205-269-30 (Tadalafil Label 5mg)

The label for Tadalafil 5 mg film-coated tablets by Proficient Rx LP displays product details including the strength (5 mg), quantity (#30 tablets), and description of the tablets as light yellow, almond-shaped, biconvex, with debossed markings. It lists the manufacturer as Intas Pharmaceuticals Limited in India and includes storage instructions at 25°C (77°F). The label also shows the NDC 71205-269-30 and indicates the product is prescription only.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of tadalafil showing its molecular framework with characteristic fused rings and functional groups, as depicted in the product data for tadalafil tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.